A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Summary

This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.

Timeline

Start

2022-12-19

Primary completion

2026-09-30

Completion

2027-12-31

Drugs

Indications